ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer.

求助中 10 由 W 发布于 2026/4/10 9:42:38

DOI:10.1016/j.jtho.2026.103708
作者：Paul Stockhammer,?Talal El Zarif,?Jacob L Schillo,?Fangyong Li,?Sarah B Goldberg,?Katerina Politi,?Michael J Grant
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: ERBB2 mutations occur in 1-4% of all non-small cell lung cancers (NSCLCs). Trastuzumab-deruxtecan and the novel ERBB2 tyrosine kinase inhibitors zongertinib and sevabertinib are

应助信息

等您来应助

上传文件

15小时前

Book学术机器人

2026/4/10 9:42:38 未找到该文献，机器人已退出，请等待人工下载

2026/4/10 9:42:38 Book学术AI机器人收到请求，开始寻找文献

2026/4/10 9:42:38 已向机器人发送请求

15小时前

W 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Thieme Medical PublishersDeoxyfluorination: A Detailed Overview of Recent Developments